ASX:GTG

Genetic Technologies Competitors

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Genetic Technologies (ASX:GTG) Vs. BUX, IME, BD1, CRL, CTE, and DVL

Should you be buying GTG stock or one of its competitors? Companies in the industry of "diagnostics & research" are considered alternatives and competitors to Genetic Technologies, including (BUX) (BUX), 12144 (IME), BARD1 Life Sciences (BD1), Charles River Laboratories International (CRL), Cryosite (CTE), and dorsaVi (DVL).

(BUX) (CNSX:BUX) and Genetic Technologies (ASX:GTG) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, analyst recommendations, earnings, risk and institutional ownership.

Analyst Ratings

This is a summary of recent ratings for (BUX) and Genetic Technologies, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
(BUX)0000N/A
Genetic Technologies0000N/A

Valuation and Earnings

This table compares (BUX) and Genetic Technologies' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
(BUX)N/AN/AN/AN/AN/A
Genetic Technologies$25,714.000.00$-9,016,729.60A$0.00N/A

(BUX) has higher earnings, but lower revenue than Genetic Technologies.

Profitability

This table compares (BUX) and Genetic Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
(BUX)N/AN/AN/A
Genetic TechnologiesN/AN/AN/A

Summary

Genetic Technologies beats (BUX) on 1 of the 1 factors compared between the two stocks.

Genetic Technologies (ASX:GTG) and 12144 (CNSX:IME) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability and institutional ownership.

Profitability

This table compares Genetic Technologies and 12144's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Genetic TechnologiesN/AN/AN/A
12144N/AN/AN/A

Valuation and Earnings

This table compares Genetic Technologies and 12144's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genetic Technologies$25,714.000.00C$-9,016,729.60A$0.00N/A
12144N/AN/AN/AN/AN/A

12144 has lower revenue, but higher earnings than Genetic Technologies.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Genetic Technologies and 12144, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Genetic Technologies0000N/A
121440000N/A

Summary

Genetic Technologies beats 12144 on 1 of the 1 factors compared between the two stocks.

BARD1 Life Sciences (ASX:BD1) and Genetic Technologies (ASX:GTG) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability and valuation.

Analyst Ratings

This is a breakdown of recent ratings and price targets for BARD1 Life Sciences and Genetic Technologies, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BARD1 Life Sciences0000N/A
Genetic Technologies0000N/A

Earnings & Valuation

This table compares BARD1 Life Sciences and Genetic Technologies' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BARD1 Life Sciences$612,251.000.00$-6,644,706.43A($0.08)N/A
Genetic Technologies$25,714.000.00$-9,016,729.60A$0.00N/A

BARD1 Life Sciences has higher revenue and earnings than Genetic Technologies.

Profitability

This table compares BARD1 Life Sciences and Genetic Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BARD1 Life SciencesN/AN/AN/A
Genetic TechnologiesN/AN/AN/A

Summary

BARD1 Life Sciences beats Genetic Technologies on 2 of the 3 factors compared between the two stocks.

Genetic Technologies (ASX:GTG) and Charles River Laboratories International (CNSX:CRL) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, profitability, risk and earnings.

Profitability

This table compares Genetic Technologies and Charles River Laboratories International's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Genetic TechnologiesN/AN/AN/A
Charles River Laboratories InternationalN/AN/AN/A

Earnings & Valuation

This table compares Genetic Technologies and Charles River Laboratories International's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genetic Technologies$25,714.000.00$-9,016,729.60A$0.00N/A
Charles River Laboratories InternationalN/AN/AN/AN/AN/A

Charles River Laboratories International has lower revenue, but higher earnings than Genetic Technologies.

Analyst Recommendations

This is a summary of current recommendations for Genetic Technologies and Charles River Laboratories International, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Genetic Technologies0000N/A
Charles River Laboratories International0000N/A

Summary

Genetic Technologies beats Charles River Laboratories International on 1 of the 1 factors compared between the two stocks.

Cryosite (ASX:CTE) and Genetic Technologies (ASX:GTG) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Cryosite and Genetic Technologies, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cryosite0000N/A
Genetic Technologies0000N/A

Earnings and Valuation

This table compares Cryosite and Genetic Technologies' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cryosite$9.71 million0.00$515,455.60A$0.01N/A
Genetic Technologies$25,714.000.00$-9,016,729.60A$0.00N/A

Cryosite has higher revenue and earnings than Genetic Technologies.

Profitability

This table compares Cryosite and Genetic Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CryositeN/AN/AN/A
Genetic TechnologiesN/AN/AN/A

Summary

Cryosite beats Genetic Technologies on 3 of the 3 factors compared between the two stocks.

dorsaVi (ASX:DVL) and Genetic Technologies (ASX:GTG) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability.

Earnings & Valuation

This table compares dorsaVi and Genetic Technologies' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
dorsaVi$1.65 million0.00$-3,158,396.93A($0.01)N/A
Genetic Technologies$25,714.000.00$-9,016,729.60A$0.00N/A

dorsaVi has higher revenue and earnings than Genetic Technologies.

Analyst Recommendations

This is a summary of recent ratings and price targets for dorsaVi and Genetic Technologies, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
dorsaVi0000N/A
Genetic Technologies0000N/A

Profitability

This table compares dorsaVi and Genetic Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
dorsaViN/AN/AN/A
Genetic TechnologiesN/AN/AN/A

Summary

dorsaVi beats Genetic Technologies on 2 of the 3 factors compared between the two stocks.


Genetic Technologies Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
BUX
(BUX)
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
IME
12144
0.5N/AN/AC$0.00N/A0.00High Trading Volume
Gap Down
BD1
BARD1 Life Sciences
0.5N/AN/A$0.00$612,251.000.00High Trading Volume
Gap Up
CRL
Charles River Laboratories International
0.5N/AN/A$0.00N/A0.00Gap Up
CTE
Cryosite
0.6N/AN/A$0.00$9.71 million0.00High Trading Volume
Gap Up
DVL
dorsaVi
0.5N/AN/A$0.00$1.65 million0.00High Trading Volume
Gap Up
Epigenomics logo
EPGNY
Epigenomics
0.6$13.77flat$0.00N/A0.00
ETAH
Eternity Healthcare
0.6$0.00flat$0.00N/A0.00Gap Up
GSS
Genetic Signatures
0.0N/AN/A$0.00$29.13 million0.00High Trading Volume
IBX
Imagion Biosystems
0.6N/AN/A$0.00$2.70 million0.00High Trading Volume
Gap Up
IDX
Integral Diagnostics
0.8N/AN/A$0.00$314.82 million0.00High Trading Volume
Gap Up
LSH
Lifespot Health
0.5N/AN/A$0.00$22,127.000.00High Trading Volume
Gap Up
MEDD
Medical Imaging
0.4$0.01flat$0.00N/A0.00Gap Down
OSL
OncoSil Medical
0.5N/AN/A$0.00$2.22 million0.00High Trading Volume
Gap Up
PRLX
Parallax Health Sciences
0.5$0.02flat$0.00N/A0.00Gap Up
RHY
Rhythm Biosciences
0.0N/AN/A$0.00$1.21 million0.00High Trading Volume
Sartorius Aktiengesellschaft logo
SRT3
Sartorius Aktiengesellschaft
0.6$459.00flat$0.00N/A0.00High Trading Volume
Siemens Healthineers logo
SMMNY
Siemens Healthineers
0.5$28.08flat$0.00N/A0.00
SIL
Smiles Inclusive
0.4N/AN/A$0.00$36.48 million0.00High Trading Volume
Gap Up
VHT
Volpara Health Technologies
0.5N/AN/A$0.00$15.22 million0.00High Trading Volume
Gap Up
OBJ
Wellfully Limited (OBJ.AX)
0.0N/AN/A$0.00$1.48 million0.00High Trading Volume
WUXIF
WuXi AppTec
1.0$18.50flat$0.00N/A0.00Gap Down
This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.